The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Treatment patterns, biomarker testing, and outcomes in patients with nonsquamous non-small cell lung cancer (NSCLC) receiving second-line treatment in the US Oncology network.
IWen Pan
No relevant relationships to disclose
Rajiv Mallick
Employment or Leadership Position - Daiichi Sankyo
Stock Ownership - Daiichi Sankyo
Rahul Dhanda
No relevant relationships to disclose
Eric S. Nadler
Consultant or Advisory Role - Genentech (U); Lilly (U); Pfizer (U)
Honoraria - Genentech; Lilly; Pfizer